KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Construction in Progress: 2013-2017

  • Regeneron Pharmaceuticals' Construction in Progress rose 28.20% to $408.9 million in Q4 2017 from the same period last year, while for Dec 2017 it was $408.9 million, marking a year-over-year increase of 28.20%. This contributed to the annual value of $408.9 million for FY2017, which is 28.20% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Construction in Progress stood at $408.9 million for Q4 2017, which was up 28.20% from $318.9 million recorded in Q4 2016.
  • In the past 5 years, Regeneron Pharmaceuticals' Construction in Progress ranged from a high of $579.8 million in Q4 2015 and a low of $142.4 million during Q4 2013.
  • In the last 3 years, Regeneron Pharmaceuticals' Construction in Progress had a median value of $408.9 million in 2017 and averaged $435.9 million.
  • Its Construction in Progress has fluctuated over the past 5 years, first surged by 231.69% in 2014, then tumbled by 45.00% in 2016.
  • Regeneron Pharmaceuticals' Construction in Progress (Quarterly) stood at $142.4 million in 2013, then skyrocketed by 231.69% to $472.2 million in 2014, then increased by 22.79% to $579.8 million in 2015, then slumped by 45.00% to $318.9 million in 2016, then increased by 28.20% to $408.9 million in 2017.
  • Its last three reported values are $408.9 million in Q4 2017, $318.9 million for Q4 2016, and $579.8 million during Q4 2015.